Long-term results of bioprosthetic tricuspid valve replacement: an analysis of 25 years of experience
Authors:
- 6 December 2012
- journal article
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 61 (3) , 133-138
Abstract
Current knowledge in long-term results of tricuspid valve replacement is limited. Present study reviews our experience from a consecutive series. We retrospectively studied the early and late results of 32 consecutive patients (7 male and 25 female; mean age 60.2 ± 18.1 years) undergoing bioprosthetic tricuspid valve replacement between 1985 and 2010. The etiology is rheumatic in 38 %, congenital in 3 %, endocarditis in 9 %, and functional in 50 %. Patients underwent isolated valve replacement. The remaining underwent combined aortic and tricuspid (n = 5, 16 %), mitral tricuspid (n = 15, 47 %), and aortic, mitral, and tricuspid (n = 1, 3 %) valve replacement. Preoperative liver dysfunction was evaluated using Model for End-stage Liver Disease (MELD) score. Mean follow-up was 5.6 ± 6.8 years (ranging from 0 to 25.0 years). Hospital mortality was 19 %. On univariate logistic regression analysis, NYHA class IV (p = 0.039, odds ratio 11.3, 95 % confidence interval 1.2–112.5), MELD score (>10) (p = 0.011, odds ratio 21.0, 95 % confidence interval 12.0–222.0) and congestive liver (p = 0.05, odds ratio 9.4, 95 % confidence interval 1.0–93.5) were incremental risk factors for hospital death. The 15- and 25-year actuarial survival were 56.5 ± 10.3 % and 45 ± 13.0 %, respectively. Multivariate analysis using Cox proportional hazard model showed MELD score (p = 0.024, hazard ratio 7.0, 95 % confidence interval 2.1–23.9) and postoperative pulmonary hypertension (p = 0.012, hazard ratio 4.4, 95 % confidence interval 1.4–14.1) were significantly associated with decreased survival. At 15 years, freedom rates from tricuspid valve reoperation, anticoagulation-related bleeding, and valve related events were 85.7 ± 13.2 %,95.7 ± 4.3 % and 81.8 ± 13.2 %, respectively. The linearized incidence of structural valve deterioration was 0.50 %/patient-year, anticoagulation-related bleeding was 0.94 %/patient-year, and valve-related events were 1.52 %/patient-year. Preoperative hepatic congestion and liver dysfunction which were indicated by the MELD score >10 were associated with poor outcome for patients undergoing tricuspid valve replacement. The MELD score is useful to predict the morality among these patients.Keywords
This publication has 22 references indexed in Scilit:
- Model for End-Stage Liver Disease Predicts Mortality for Tricuspid Valve SurgeryThe Annals of Thoracic Surgery, 2009
- Tricuspid Valve Replacement: An Analysis of Risk Factors and OutcomesThe Thoracic and Cardiovascular Surgeon, 2008
- What to expect after tricuspid valve replacement? Long-term resultsEuropean Journal of Cardio-Thoracic Surgery, 2007
- Long-Term Clinical Results of Tricuspid Valve ReplacementThe Annals of Thoracic Surgery, 2006
- Model for End-Stage Liver Disease (MELD) Predicts Nontransplant Surgical Mortality in Patients With CirrhosisAnnals of Surgery, 2005
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001
- Ten-year experience with the Carpentier-Edwards pericardial xenograft in the tricuspid positionThe Journal of Thoracic and Cardiovascular Surgery, 1996
- In-hospital and long-term outcome after porcine tricuspid valve replacementThe Journal of Thoracic and Cardiovascular Surgery, 1995
- The valve choice in tricuspid valve replacement: 25 years of experienceEuropean Journal of Cardio-Thoracic Surgery, 1995
- Early and Late Phase Events Following Bioprosthetic Tricuspid Valve ReplacementJournal of Cardiac Surgery, 1992